论文部分内容阅读
目的:评价注射用头孢他啶与痰热清注射液联用对慢性阻塞性肺疾病(COPD)患者的临床疗效及安全性。方法:选取2011年12月—2014年9月收治的COPD患者88例为研究对象,将其分为对照组和观察组,各44例;对照组患者给予注射用头孢他啶治疗,观察组患者给予注射用头孢他啶与痰热清注射液联用治疗,分析两组患者治疗后的总有效率和不良反应的发生情况。结果:观察组患者治疗后的总有效率为93.18%显著高于对照组为75.00%(P<0.05),其不良反应发生率为9.09%显著低于对照组为25.00%(P<0.05)。结论:注射用头孢他啶与痰热清注射液联用治疗COPD患者的疗效优于单用注射用头孢他啶治疗,且疗效较显著和安全性较高。
Objective: To evaluate the clinical efficacy and safety of ceftazidime injection combined with Tanreqing Injection in patients with chronic obstructive pulmonary disease (COPD). Methods: Eighty-eight COPD patients admitted from December 2011 to September 2014 were selected as study subjects and divided into control group and observation group, 44 cases in each. Patients in the control group were given ceftazidime for injection and patients in observation group were given injection With ceftazidime and Tanreqing injection combination therapy, analysis of the two groups of patients after treatment, the total effective rate and adverse reactions. Results: The total effective rate of the observation group after treatment was 93.18%, which was significantly higher than that of the control group (75.00%, P <0.05). The incidence of adverse reactions in the observation group was 9.09%, which was significantly lower than that in the control group (25.00%, P <0.05). Conclusion: Ceftazidime injection and Tanreqing injection combined with ceftazidime injection are superior to ceftazidim alone in the treatment of COPD patients, and the curative effect is more obvious and safe.